Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

USA - NASDAQ:AXSM - US05464T1043 - Common Stock

139.61 USD
+1.81 (+1.31%)
Last: 11/11/2025, 8:00:01 PM
139.54 USD
-0.07 (-0.05%)
After Hours: 11/11/2025, 8:00:01 PM
Fundamental Rating

2

AXSM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. AXSM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AXSM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AXSM had negative earnings in the past year.
AXSM had a negative operating cash flow in the past year.
In the past 5 years AXSM always reported negative net income.
In the past 5 years AXSM always reported negative operating cash flow.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -34.30%, AXSM perfoms like the industry average, outperforming 48.69% of the companies in the same industry.
The Return On Equity of AXSM (-311.32%) is worse than 73.30% of its industry peers.
Industry RankSector Rank
ROA -34.3%
ROE -311.32%
ROIC N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

With an excellent Gross Margin value of 91.86%, AXSM belongs to the best of the industry, outperforming 94.24% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for AXSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AXSM has been increased compared to 1 year ago.
Compared to 5 years ago, AXSM has more shares outstanding
The debt/assets ratio for AXSM is higher compared to a year ago.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 4.40 indicates that AXSM is not in any danger for bankruptcy at the moment.
AXSM's Altman-Z score of 4.40 is fine compared to the rest of the industry. AXSM outperforms 76.96% of its industry peers.
AXSM has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of AXSM (2.61) is worse than 80.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Altman-Z 4.4
ROIC/WACCN/A
WACC9.01%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 1.57 indicates that AXSM should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.57, AXSM is doing worse than 67.54% of the companies in the same industry.
A Quick Ratio of 1.50 indicates that AXSM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.50, AXSM is doing worse than 61.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.5
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

AXSM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.48%, which is quite impressive.
The Revenue has grown by 65.83% in the past year. This is a very strong growth!
EPS 1Y (TTM)28.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.85%
Revenue 1Y (TTM)65.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%63.22%

3.2 Future

Based on estimates for the next years, AXSM will show a very strong growth in Earnings Per Share. The EPS will grow by 38.91% on average per year.
AXSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.32% yearly.
EPS Next Y38.6%
EPS Next 2Y46.26%
EPS Next 3Y49.73%
EPS Next 5Y38.91%
Revenue Next Year60.86%
Revenue Next 2Y57.63%
Revenue Next 3Y55.8%
Revenue Next 5Y46.32%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
AXSM is valuated quite expensively with a Price/Forward Earnings ratio of 167.57.
Based on the Price/Forward Earnings ratio, AXSM is valued a bit cheaper than the industry average as 69.11% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 33.72, AXSM is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 167.57
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as AXSM's earnings are expected to grow with 49.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.26%
EPS Next 3Y49.73%

More info and screens

0

5. Dividend

5.1 Amount

AXSM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (11/11/2025, 8:00:01 PM)

After market: 139.54 -0.07 (-0.05%)

139.61

+1.81 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-16 2026-02-16/amc
Inst Owners76.11%
Inst Owner Change-1.18%
Ins Owners1.15%
Ins Owner Change-1.66%
Market Cap6.97B
Revenue(TTM)561.26M
Net Income(TTM)-229.53M
Analysts86.15
Price Target180.65 (29.4%)
Short Float %8.31%
Short Ratio6.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.42%
Min EPS beat(2)-6.47%
Max EPS beat(2)13.31%
EPS beat(4)2
Avg EPS beat(4)-8.01%
Min EPS beat(4)-48.67%
Max EPS beat(4)13.31%
EPS beat(8)3
Avg EPS beat(8)-17.43%
EPS beat(12)4
Avg EPS beat(12)-9.71%
EPS beat(16)7
Avg EPS beat(16)-5.43%
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.13%
Max Revenue beat(2)6.01%
Revenue beat(4)2
Avg Revenue beat(4)1.86%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)6.01%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)9
Avg Revenue beat(12)24.39%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.88%
PT rev (3m)0.28%
EPS NQ rev (1m)1.61%
EPS NQ rev (3m)-7.45%
EPS NY rev (1m)2.04%
EPS NY rev (3m)-0.96%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)1.05%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)1.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 167.57
P/S 12.41
P/FCF N/A
P/OCF N/A
P/B 94.49
P/tB 356.18
EV/EBITDA N/A
EPS(TTM)-4.67
EYN/A
EPS(NY)0.83
Fwd EY0.6%
FCF(TTM)-2.03
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS11.25
BVpS1.48
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.3%
ROE -311.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.86%
FCFM N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.95%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.5
Altman-Z 4.4
F-Score5
WACC9.01%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.85%
EPS Next Y38.6%
EPS Next 2Y46.26%
EPS Next 3Y49.73%
EPS Next 5Y38.91%
Revenue 1Y (TTM)65.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%63.22%
Revenue Next Year60.86%
Revenue Next 2Y57.63%
Revenue Next 3Y55.8%
Revenue Next 5Y46.32%
EBIT growth 1Y29.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3Y55.68%
EBIT Next 5Y45%
FCF growth 1Y29.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.05%
OCF growth 3YN/A
OCF growth 5YN/A

AXSOME THERAPEUTICS INC / AXSM FAQ

What is the fundamental rating for AXSM stock?

ChartMill assigns a fundamental rating of 2 / 10 to AXSM.


What is the valuation status of AXSOME THERAPEUTICS INC (AXSM) stock?

ChartMill assigns a valuation rating of 1 / 10 to AXSOME THERAPEUTICS INC (AXSM). This can be considered as Overvalued.


How profitable is AXSOME THERAPEUTICS INC (AXSM) stock?

AXSOME THERAPEUTICS INC (AXSM) has a profitability rating of 1 / 10.


How financially healthy is AXSOME THERAPEUTICS INC?

The financial health rating of AXSOME THERAPEUTICS INC (AXSM) is 2 / 10.